Annals of Hematology

, Volume 86, Issue 5, pp 311–327

Diagnostic pathways in acute leukemias: a proposal for a multimodal approach


    • MLL Munich Leukemia Laboratory
  • Ulrike Bacher
    • Bone Marrow TransplantationUniversity Hospital Hamburg Eppendorf
  • Wolfgang Kern
    • MLL Munich Leukemia Laboratory
  • Susanne Schnittger
    • MLL Munich Leukemia Laboratory
  • Claudia Haferlach
    • MLL Munich Leukemia Laboratory
Review Article

DOI: 10.1007/s00277-007-0253-2

Cite this article as:
Haferlach, T., Bacher, U., Kern, W. et al. Ann Hematol (2007) 86: 311. doi:10.1007/s00277-007-0253-2


Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) each represent a heterogeneous complex of disorders, which result from diverse mechanisms of leukemogenesis. Modern therapeutic concepts are based on individual risk stratification at diagnosis and during follow-up. For some leukemia subtypes such as AML M3/M3v with t(15;17)/PMLRARA or Philadelphia-positive ALL targeted therapy options are available. Thus, optimal therapeutic conditions are based on exact classification of the acute leukemia subtype at diagnosis and are guided by exact and sensitive quantification of minimal residual disease during complete hematologic remission. Today, a multimodal diagnostic approach combining cytomorphology, multiparameter flow cytometry, chromosome banding analysis, accompanied by diverse fluorescence in situ hybridization techniques, and molecular analyses is needed to meet these requirements. As the diagnostic process becomes more demanding with respect to experience of personnel, time, and costs due to the expansion of methods, algorithms, which guide the diagnostic procedure from basic to more specific methods and which lead finally to a synopsis of the respective results, are essential for modern diagnostics and therapeutic concepts.


Acute leukemiasDiagnosisCytogeneticsPCRMultiparameter flow cytometry

Copyright information

© Springer-Verlag 2007